Article Text

Download PDFPDF
Do we really need continuous vancomycin infusion in neonates?
  1. Samira Samiee-Zafarghandy1,
  2. John N van den Anker1,2
  1. 1Division of Pediatric Clinical Pharmacology, Children's National Medical Center, Washington, District of Columbia, USA
  2. 2Departments of Pediatrics, Pharmacology, Physiology and Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA
  1. Correspondence to Dr Samira Samiee-Zafarghandy, Division of Pediatric Clinical Pharmacology, Children's National Medical Center, 111 Michigan Ave. NW. Washington, DC 20010, USA; sa.samira{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The interesting work of Zhao et al,1 in the June issue of the journal, recommends the use of a patient-tailored dosing regimen in an attempt to optimise continuous-infusion vancomycin (CIV) therapy in the newborn population.

Despite the increasing use of CIV therapy during the past 10 years in neonates and young infants, the data on pharmacokinetics and dosing regimen of this drug are significantly lacking. Zhao et al1 chose to investigate the results of vancomycin therapeutic drug monitoring under three different regimens and to develop an optimised dosing model with the aim to decrease the number of off-target vancomycin …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.